Here are four notes:
1. Epi proColon is indicated for colorectal cancer screening in average-risk patients who choose not to undergo CRC screening by recommended methods such as colonoscopy and fecal immunochemical tests.
2. The test only requires a blood sample drawn from the patient as part of routine healthcare provider visits.
3. The sample is then analyzed at a local or regional diagnostic laboratory.
4. Epi proColon will be made available in the United States under a joint commercialization agreement with its strategic partner Polymedco.
More articles on GI/endoscopy:
Gastroenterologist to know: Dr. Elaine Barfield of NewYork-Presbyterian Hospital
Cancer recurrence high among patients with HCV-related hepatocellular carcinoma: 3 key insights
Boston Medical Center names Dr. Jason Hall colon & rectal surgery chief: 5 notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.